You are here: Welcome to the MPKB » Welcome to the MPKB » Starting the Marshall Protocol » Safety warnings for the Marshall Protocol
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Last revisionBoth sides next revision
home:starting:safety_warnings [07.03.2017] – [The Marshall Protocol is a serious commitment] sallieqhome:starting:safety_warnings [10.19.2018] – [Notes and comments] sallieq
Line 31: Line 31:
   * why higher than normal doses of olmesartan (Benicar) are required   * why higher than normal doses of olmesartan (Benicar) are required
   * why the use of antibiotics while taking olmesartan can provoke dangerous levels of immunopathology   * why the use of antibiotics while taking olmesartan can provoke dangerous levels of immunopathology
-  * why the use of azithromycin is considered particularly dangerous+  * why the use of telmisartan or azithromycin is considered particularly dangerous
  
 It has been the experience of the staff and volunteers of Autoimmunity Research Foundation that those patients who understand the rationale for the different components and instructions of the MP have the most success and best treatment outcomes. It has been the experience of the staff and volunteers of Autoimmunity Research Foundation that those patients who understand the rationale for the different components and instructions of the MP have the most success and best treatment outcomes.
  
  
-===== Patients' physicians must understand the Marshall Protocol =====+===== Patients' physicians benefit from understanding the Marshall Protocol =====
  
 Some [[physician|physicians]] consent to treat a patient with the MP after a cursory examination of the various [[home:publications|presentations or papers]] which describe it.  Some [[physician|physicians]] consent to treat a patient with the MP after a cursory examination of the various [[home:publications|presentations or papers]] which describe it. 
  
 The MP involves signs and symptoms of disease that may be unfamiliar to many clinical practitioners: The MP involves signs and symptoms of disease that may be unfamiliar to many clinical practitioners:
-  * Patients on the MP may see temporary increases in inflammatory markers and symptom severity due to [[home:mp:immunopathology|immunopathology]].+  * Patients on the MP will see temporary increases in inflammatory markers and symptom severity due to [[home:mp:immunopathology|immunopathology]].
   * Patients on the MP may have levels of [[home:tests:25d|25-D]] that decrease into the range of undetectability by laboratory testing while continuing to maintain normal levels of the active metabolite [[home:tests:125d|1,25D]].    * Patients on the MP may have levels of [[home:tests:25d|25-D]] that decrease into the range of undetectability by laboratory testing while continuing to maintain normal levels of the active metabolite [[home:tests:125d|1,25D]]. 
   * Olmesartan (Benicar) should not be discontinued in an [[home:special:hospitals_emergencies|acute emergency situation]]. More than one death has been reported following the abrupt withdrawal of olmesartan from a patient in such situations.    * Olmesartan (Benicar) should not be discontinued in an [[home:special:hospitals_emergencies|acute emergency situation]]. More than one death has been reported following the abrupt withdrawal of olmesartan from a patient in such situations. 
Line 66: Line 66:
  
  
-===== Immunopathology is dangerous and may be difficult to control =====+===== Immunopathology could become dangerous and may be difficult to control =====
  
 <mainarticle> [[home:mp:immunopathology|Immunopathology]] </article> <mainarticle> [[home:mp:immunopathology|Immunopathology]] </article>
Line 87: Line 87:
  
   * Updated wording, but still think it could be made even better with more work. --Joyful May'13   * Updated wording, but still think it could be made even better with more work. --Joyful May'13
-  * added "Xarelto increases the risk of bleeding and can cause serious or fatal bleeding. A specific antidote for rivaroxaban is not available. Because of high plasma protein binding, rivaroxaban is not expected to be dialyzable." --Sallie Q May15  + 
-  * altered 3rd line to 'sufficient olmesartan medoxomil (Benicar) to ensure that patient does not run out if there is a delay in delivery or in renewing prescription' --- //Sallie Q 11.02.2016//+ 
home/starting/safety_warnings.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.